{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:07:44Z","timestamp":1753891664163,"version":"3.41.2"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Becker muscular dystrophy (BMD) is an X-linked recessive inherited disorder characterized by slowly progressing muscle weakness of the legs and pelvis, caused by mutations in the DMD gene, which encodes dystrophin protein. Different from Duchenne Muscular Dystrophy (DMD), in which dystrophin is completely absent in muscle tissue, while in BMD, the dystrophin gene can express some protein, but not enough. It has also been shown that a proportion of patients with DMD suffer from attention deficit hyperactivity disorder (ADHD), and the use of the stimulant methylphenidate has been suggested for the treatment of patients with DMD in combination with ADHD. However, there are no case reports on the treatment of co-occurring ADHD in BMD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>The patient was a 9-year-old boy who presented with elevated serum creatine kinase levels and inattention. The magnetic resonance imaging of the thigh muscles of both lower limbs suggested partial fatty infiltration of the gluteus maximus muscle bilaterally, and a novel heterozygous mutation (c.31\u2009+\u20096\u2009T\u2009&amp;gt;\u2009C) was identified in the DMD gene by Next Generation Sequencing (NGS) and the sequencing results were verified by using the Sanger method. The child was also diagnosed with co-morbid ADHD after a thorough evaluation and considering this new diagnosis, we started treatment with methylphenidate at a dose of 18\u2009mg\/day, and after 6\u2009months of treatment, he showed a significant improvement in his attention span.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We identified a novel heterozygous mutation in the DMD gene, which will expand the spectrum of pathogenic variants in BMD. Simultaneously, methylphenidate treatment significantly improved attention in children with BMD co-morbid with ADHD, and this study provides value for future therapeutic protocols for BMD combined with ADHD. However, to the best of our knowledge, this is the only reported case report on the treatment of BMD co-morbid ADHD. So further studies are needed to determine the interrelationship between these disorders and their treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnins.2024.1459582","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T06:27:16Z","timestamp":1732602436000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Methylphenidate treatment of a Chinese boy with Becker muscular dystrophy combined with attention deficit hyperactivity disorder: a case report"],"prefix":"10.3389","volume":"18","author":[{"given":"Fang","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/brain\/awf012","article-title":"Brain function in Duchenne muscular dystrophy","volume":"125","author":"Anderson","year":"2002","journal-title":"Brain"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-4006","article-title":"Implementation of Duchenne muscular dystrophy care considerations","volume":"142","author":"Andrews","year":"2018","journal-title":"Pediatrics"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e0250420","DOI":"10.1371\/journal.pone.0250420","article-title":"Neural substrates of neuropsychological profiles in dystrophynopathies: a pilot study of diffusion tractography imaging","volume":"16","author":"Biagi","year":"2021","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"CD009068","DOI":"10.1002\/14651858.CD009068.pub3","article-title":"Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy","volume":"2020","author":"Bourke","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00787-016-0831-8","article-title":"Predictors of persistence of ADHD into adulthood: a systematic review of the literature and meta-analysis","volume":"25","author":"Caye","year":"2016","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/mus.24880","article-title":"Twenty-year follow-up of newborn screening for patients with muscular dystrophy","volume":"53","author":"Chung","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.euroneuro.2012.11.012","article-title":"European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"23","author":"Coghill","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00787-013-0421-y","article-title":"Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit\/hyperactivity disorder: results from a randomized, controlled trial","volume":"23","author":"Coghill","year":"2014","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJMra1917069","article-title":"Pharmacologic treatment of attention deficit-hyperactivity disorder","volume":"383","author":"Cortese","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1017\/s0012162201000913","article-title":"Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients","volume":"43","author":"Cotton","year":"2001","journal-title":"Dev. Med. Child Neurol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.pediatrneurol.2011.08.003","article-title":"Neurocognitive profiles in Duchenne muscular dystrophy and gene mutation site","volume":"45","author":"D\u2019Angelo","year":"2011","journal-title":"Pediatr. Neurol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s40263-013-0104-8","article-title":"Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit\/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study","volume":"27","author":"Dittmann","year":"2013","journal-title":"CNS Drugs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.nmd.2016.10.005","article-title":"Decreased cerebral perfusion in Duchenne muscular dystrophy patients","volume":"27","author":"Doorenweerd","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"18168","DOI":"10.3390\/molecules201018168","article-title":"Duchenne muscular dystrophy: from diagnosis to therapy","volume":"20","author":"Falzarano","year":"2015","journal-title":"Molecules"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/wnl.55.4.559","article-title":"Loss of Dp140 dystrophin isoform and intellectual impairment in Duchenne dystrophy","volume":"55","author":"Felisari","year":"2000","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"104648","DOI":"10.1016\/j.neubiorev.2022.104648","article-title":"Cognitive profile and neuropsychiatric disorders in Becker muscular dystrophy: a systematic review of literature","volume":"137","author":"Ferrero","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000068446","article-title":"The heart in human dystrophinopathies","volume":"99","author":"Finsterer","year":"2003","journal-title":"Cardiology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1177\/0883073807309775","article-title":"Neuropsychiatric disorders in males with duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive--compulsive disorder","volume":"23","author":"Hendriksen","year":"2008","journal-title":"J. Child Neurol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40263-017-0410-7","article-title":"Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and Meta-analysis of trials of methylphenidate, amphetamines and atomoxetine","volume":"31","author":"Hennissen","year":"2017","journal-title":"CNS Drugs"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ejpn.2015.04.005","article-title":"Pain in adolescents with spinal muscular atrophy and Duchenne and Becker muscular dystrophy","volume":"19","author":"Lager","year":"2015","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/mus.26750","article-title":"Neurodevelopmental, behavioral, and emotional symptoms in Becker muscular dystrophy","volume":"61","author":"Lambert","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/0883073817701368","article-title":"Secondary conditions among males with Duchenne or Becker muscular dystrophy","volume":"32","author":"Latimer","year":"2017","journal-title":"J. Child Neurol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejpn.2018.09.005","article-title":"Methylphenidate use in males with Duchenne muscular dystrophy and a comorbid attention-deficit hyperactivity disorder","volume":"23","author":"Lionarons","year":"2019","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1017\/s0317167100011896","article-title":"A population-based study of dystrophin mutations in Canada","volume":"38","author":"Mah","year":"2011","journal-title":"Can. J. Neurol. Sci."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/ph8020303","article-title":"X-linked dilated cardiomyopathy: a Cardiospecific phenotype of Dystrophinopathy","volume":"8","author":"Nakamura","year":"2015","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1002\/acn3.51925","article-title":"Natural history of Becker muscular dystrophy: a multicenter study of 225 patients","volume":"10","author":"Nakamura","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00787-018-1125-0","article-title":"Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis","volume":"27","author":"Padilha","year":"2018","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jpeds.2012.03.020","article-title":"Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation","volume":"161","author":"Pane","year":"2012","journal-title":"J. Pediatr."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2024-065787","article-title":"Treatments for ADHD in children and adolescents: a systematic review","volume":"153","author":"Peterson","year":"2024","journal-title":"Pediatrics"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s10072-023-07169-x","article-title":"Cognitive abnormalities in Becker muscular dystrophy: a mysterious link between dystrophin deficiency and executive functions","volume":"45","author":"Pezzoni","year":"2024","journal-title":"Neurol. Sci."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","article-title":"The worldwide prevalence of ADHD: a systematic review and metaregression analysis","volume":"164","author":"Polanczyk","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"CD009996","DOI":"10.1002\/14651858.CD009996.pub2","article-title":"Amphetamines for attention deficit hyperactivity disorder. (ADHD) in children and adolescents","volume":"2","author":"Punja","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/dmcn.12922","article-title":"Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations","volume":"58","author":"Ricotti","year":"2016","journal-title":"Dev. Med. Child Neurol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.biopsych.2013.10.016","article-title":"Effects of stimulants on brain function in attention-deficit\/hyperactivity disorder: a systematic review and meta-analysis","volume":"76","author":"Rubia","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13018-022-02996-8","article-title":"Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis","volume":"17","author":"Salari","year":"2022","journal-title":"J. Orthop. Surg. Res."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/s2215-0366(17)30167-0","article-title":"ADHD in children and young people: prevalence, care pathways, and service provision","volume":"5","author":"Sayal","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.neubiorev.2013.03.016","article-title":"Neuropsychological and neurobehavioral functioning in Duchenne muscular dystrophy: a review","volume":"37","author":"Snow","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref39","first-page":"9","article-title":"Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene","volume":"34","author":"Taglia","year":"2015","journal-title":"Acta Myol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.nmd.2023.05.011","article-title":"Psychopharmaceutical treatment for neurobehavioral problems in Duchenne muscular dystrophy: a descriptive study using real-world data","volume":"33","author":"Weerkamp","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2528","article-title":"Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00415-022-11432-0","article-title":"Clinical, muscle imaging, and genetic characteristics of dystrophinopathies with deep-intronic DMD variants","volume":"270","author":"Xie","year":"2023","journal-title":"J. Neurol."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/jmedgenet-2020-107113","article-title":"Practical approach to the genetic diagnosis of unsolved dystrophinopathies: a stepwise strategy in the genomic era","volume":"58","author":"Xie","year":"2021","journal-title":"J. Med. Genet."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0883073807307975","article-title":"North: cognitive and psychological profile of males with Becker muscular dystrophy","volume":"23","author":"Young","year":"2008","journal-title":"J. Child Neurol."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2024.1459582\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T06:27:19Z","timestamp":1732602439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2024.1459582\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":44,"alternative-id":["10.3389\/fnins.2024.1459582"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2024.1459582","relation":{},"ISSN":["1662-453X"],"issn-type":[{"type":"electronic","value":"1662-453X"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"article-number":"1459582"}}